

OSIRIS THERAPEUTICS, INC.

Reported by PALCZUK LINDA

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 09/21/17 for the Period Ending 07/10/17

Address 7015 ALBERT EINSTEIN DRIVE

COLUMBIA, MD, 21046

Telephone 443-545-1819

CIK 0001360886

Symbol OSIR

SIC Code 2836 - Biological Products, (No Diagnostic Substances)

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31





[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *	S 2						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Palczuk Linda	OSIR l	RIS TH	ERAPI	EUTI	ICS	, INC.	[OSII	Director	,	10	% Owner	
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)					~	X Officer (give title below) Other (specify below) President & CEO					
7015 ALBERT EINSTEIN DRIVE			7/1	0/201	17							
(Street)	4. If A	mendmen	t, Date C	Origina	al Fil	ed (MM/I	DD/YYYY)	6. Individual o	or Joint/G	roup Filing	Check Appl	licable Line)
COLUMBIA, MD 21046 (City) (State) (Zip)								X Form filed by	y One Repo More than (rting Person One Reporting F	erson	
Table I - Non	-Deriva	tive Secu	rities Ac	quire	d, D	isposed (of, or Be	neficially Owne	ed			
1. Title of Security (Instr. 3) 2. Trans.			3. Trans. Co (Instr. 8)	(or Dis (Instr.	posed of (E 3, 4 and 5) (A) o	r	5. Amount of Securiti Following Reported T Instr. 3 and 4)			or Indirect (I) (Instr.	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Table II - Derivative Securi	ties Ben	eficially (Code Owned (+ +	Amou puts	/	Price	, options, conve	rtible sec	urities)	4)	
Security Conversion or Exercise Price of Derivative Date Execution Date, if any (Instr. 3) (Instr. 3)	Trans. Code tr. 8)				ate Exercisable and Securities Uperivative (Instr. 3 and		Underlying Security	Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
Security	ode V	(A)		Date Exercis		Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Incentive Stock Option (right to buy) \$6.67 7/10/2017	4	25000		7/10/20 (1)		7/10/2027	Common Stock	25000	\$6.67	25000	D	

Explanation of Responses:

(1) 6,250 shares underlying this option shall vest on each of July 10, 2018, July 10, 2019, July 10, 2020, and July 10, 2021, subject to Reporting Person's continued service through the applicable vesting date.

Reporting Owners

Reporting Owner Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Palczuk Linda							
7015 ALBERT EINSTEIN DRIVE			President & CEO				
COLUMBIA, MD 21046							

Signatures

/s/ Linda Palczuk	9/21/2017
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.